Inclisiran vs PCSK9 Inhibitors: Which LDL-Lowering Option is Right for You?

Inclisiran and PCSK9 inhibitors both target the same cholesterol-regulating pathway but act in different ways, have different dosing schedules, and show slightly different side effect patterns. Understanding the biology, trial evidence, and real-world experience can help you make a more informed decision with your doctor.

Instalab Research

Lowering LDL cholesterol (LDL-C) remains one of the most reliable ways to reduce cardiovascular risk. While statins have been the standard for decades, newer injectable therapies have emerged for patients who need more aggressive LDL-C lowering or cannot tolerate statins. Two of the most important classes are:

Inclisiran - a small interfering RNA (siRNA) therapy
PCSK9 monoclonal antibodies (mAbs) - such as alirocumab and evolocumab

Although both reduce LDL-C by targeting PCSK9, they differ in where and how they work, how often they are given, and their side effect profiles.

The target: PCSK9 and LDL receptors

PCSK9 is a protein made by the liver that regulates how many LDL receptors sit on the surface of liver cells. These receptors are the main way your body removes LDL-C from the blood.

High PCSK9 activity → fewer LDL receptors → more LDL-C in circulation.
Low PCSK9 activity → more LDL receptors → more LDL-C removed from blood.

How inclisiran works: silencing the instructions

Inclisiran uses a mechanism called RNA interference.

Once injected, it enters liver cells and binds to the messenger RNA (mRNA) that carries the instructions for making PCSK9.
The bound mRNA is destroyed before it can make PCSK9 protein.
This reduces both intracellular (inside the liver) and circulating PCSK9 levels.

This is different from antibody drugs, which can only act on PCSK9 after it’s already made and in the bloodstream. Because inclisiran reduces PCSK9 production at the genetic instruction level, its effects are long-lasting, which is why it only needs dosing twice a year after the initial two doses.

How PCSK9 inhibitors work: neutralizing the protein

Alirocumab and evolocumab are monoclonal antibodies, lab-made proteins designed to attach to circulating PCSK9 in the blood.

They prevent PCSK9 from binding to LDL receptors.
As a result, LDL receptors stay active longer and can continue removing LDL-C from the blood.

However, because antibodies only neutralize PCSK9 after it’s made, the liver keeps producing PCSK9, and regular dosing every 2-4 weeks is required to maintain effect.

Pharmacokinetics and dosing

Therapy	Mechanism	Onset of Action	Dosing Frequency	Route
Inclisiran	siRNA that degrades PCSK9 mRNA	LDL-C reduction within ~14 days; maximal by 3 months	Day 0, Day 90, then every 6 months	Subcutaneous injection
PCSK9 mAbs (alirocumab, evolocumab)	Antibody binds circulating PCSK9	LDL-C reduction within days; stable effect with ongoing dosing	Every 2-4 weeks	Subcutaneous injection

Longer intervals (inclisiran) may improve adherence, particularly for patients who struggle with frequent injections. On the other hand, monoclonal antibodies allow quicker cessation if side effects occur, since their effect wears off faster.

Efficacy from clinical trials

Inclisiran: The ORION trial program showed ~50% sustained LDL-C reduction in patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia, maintained over at least 18 months.
PCSK9 mAbs: FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab) both showed ~60% LDL-C reduction plus significant reductions in cardiovascular events (heart attacks, strokes). Inclisiran’s long-term cardiovascular outcome data is still pending, though LDL-C reduction magnitude is similar.

Safety profile nuances

Inclisiran: Most common side effect is mild injection-site reaction (redness, pain). Real-world data suggest slightly higher rates of mild gastrointestinal symptoms and upper respiratory infections compared to PCSK9 mAbs.
PCSK9 mAbs: Injection-site reactions are also common. More reports of eye disorders, skin reactions, and general systemic complaints compared to inclisiran, though most are mild.
Both: Very low rates of serious adverse events. No significant increase in liver enzyme elevations, muscle damage, or neurocognitive issues in trials.

Making the choice

Convenience: Inclisiran’s twice-yearly schedule can be a game-changer for adherence.
Established outcome data: PCSK9 mAbs already have proven event reduction; inclisiran’s cardiovascular event reduction data is awaited.
Side effect tolerance: Some patients may respond differently to each class.
Reversibility: PCSK9 mAbs wear off faster if discontinued.

For patients with high cardiovascular risk who need aggressive LDL-C lowering beyond statins and ezetimibe, both are powerful tools. The best option depends on your personal cardiovascular profile, risk tolerance, and lifestyle.

References

German C et al. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. BioDrugs, 2019. https://doi.org/10.1007/s40259-019-00399-6.
Zhou S et al. A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence - what have we learned recently? Expert Opinion on Drug Safety, 2024. https://doi.org/10.1080/14740338.2024.2438753.
Katsiki N et al. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals, 2023. https://doi.org/10.3390/ph16040577.
Mulder J et al. First clinical experiences with inclisiran in a real-world setting. Journal of Clinical Lipidology, 2023. https://doi.org/10.1016/j.jacl.2023.09.005.
Wołowiec Ł et al. Inclisiran — Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9. Pharmaceutics, 2023. https://doi.org/10.3390/pharmaceutics15020323.
Catapano AL et al. New Pharmacological Approaches to Target PCSK9. Current Atherosclerosis Reports, 2020. https://doi.org/10.1007/s11883-020-00847-7.
Wang X et al. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis. Cardiovascular Diabetology, 2022. https://doi.org/10.1186/s12933-022-01542-4.